The DBS trial will look at the use of neurostimulation in people with treatment-resistant depression, which affects about 2.8 million Americans each year. The implanted device may relieve depression symptoms by changing activity patterns in the brain.
Abbott is launching a pivotal trial of its Deep Brain Stimulation (DBS) device in people with treatment-resistant depression, the company announced on 4 September.
Treatment-resistant depression (TRD) is a form of major depressive disorder that persists even after other treatment approaches, such as talk therapy, pharmaceuticals and transcranial magnetic stimulation, have been tried. About 2
Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.
Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.
At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.
Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.
